<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397579</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012013-061</org_study_id>
    <nct_id>NCT00397579</nct_id>
  </id_info>
  <brief_title>DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes</brief_title>
  <official_title>Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Combinations of biological substances in DT388IL3 fusion protein may be able to
      carry cancer killing substances directly to the cancer cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of DT388IL3 fusion
      protein and to see how well it works in treating patients with acute myeloid leukemia or
      myelodysplastic syndromes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of DT_388IL3 fusion protein in patients with
           refractory or relapsed or poor-risk acute myeloid leukemia (AML) or high-risk
           myelodysplastic syndromes (MDS).

        -  Define the dose-limiting toxicities of this regimen in these patients.

        -  Measure the pharmacokinetics of this regimen in these patients.

        -  Measure the immune responses in patients treated with this regimen.

        -  Evaluate response and correlate with disease type (relapsed/refractory or poor-risk de
           novo AML or high-risk MDS), pretreatment marrow blast percentage, and leukemia blast
           interleukin-3 receptor density.

      OUTLINE: This is a phase I, multicenter, dose-escalation study followed by a phase II,
      open-label study.

        -  Phase I: Patients receive DT_388IL3 IV over 15 minutes daily for 5 days in the absence
           of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of DT_388IL3 until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

        -  Phase II: An additional 15 patients receive DT_388IL3 at the MTD as in phase I. Patients
           undergo serum and blast collection periodically for laboratory studies, including
           analysis of expression of interleukin-3 receptors and anti-DT_388IL3 antibodies at
           baseline. Samples are also analyzed by immunoenzyme assays and flow cytometry.

      After completion of study treatment, patients are followed periodically for up to 5 years.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 27, 2017</completion_date>
  <primary_completion_date type="Actual">July 27, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months</time_frame>
    <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
Response to Treatment will be evaluated as follows:
Complete response (CR): patient has a normal whole blood count; platelets with absent blasts in peripheral blood or marrow; no evidence of nodal involvement or liver/spleen involvement; no skin lesion involvement.
Partial Response (PR); patient experiences a decrease of 50% or more in marrow blasts and skin lesions; and there is a decrease in the size of the nodes/liver/spleen.
Stable Disease (SD); failure to achieve at least PR, and there is no evidence of progression for 2 months.
Failure: death during treatment or disease progression characterized by an increase in the percentage bone marrow blast or an increase in skin or node/liver or spleen size.
Reported is the percentage of participants experiencing either CR, PR or SD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>SL-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DT388IL3</intervention_name>
    <description>Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.</description>
    <arm_group_label>SL-401</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Histologically or morphologically confirmed acute myeloid leukemia (AML), meeting
                  1 of the following criteria:

                    -  Relapsed or refractory AML after treatment with ≥ 1 prior conventional
                       induction therapy

                         -  Patients in early first relapse must not have a matched donor available
                            and/or be ineligible for allogeneic stem cell transplantation

                    -  Poor-risk AML, as defined by any of the following criteria:

                         -  Treatment-related AML, unless associated with favorable cytogenetics
                            (e.g., inversion 16, t[16;16], t[8;21], t[15;17]), and ineligible for
                            stem cell transplantation

                         -  Antecedent hematological disease (e.g., myelodysplastic syndromes,
                            myelofibrosis, or polycythemia vera) that evolved to AML (≥ 20% blasts)
                            and ineligible for stem cell transplantation

                         -  De novo AML (must be &gt; 70 years of age)

                         -  AML with unfavorable cytogenetics (e.g., abnormalities of chromosomes
                            -7, -5, 7q-, or 5q-; complex [≥ 3] abnormalities; or abnormalities of
                            11q23, excluding t[9;11], t[9;22], inversion 3, t[3;3], and t[6;9]),
                            regardless of age, and ineligible for allogeneic stem cell
                            transplantation

               -  High-risk myelodysplastic syndromes diagnosed by morphologic, histochemical, or
                  cell surface marker criteria

                    -  Resistant or intolerant to chemotherapy

                    -  Ineligible for or unwilling to undergo immediate allogeneic stem cell
                       transplantation

          -  Bone marrow index (i.e., percent cellularity × percent blasts) ≤ 40% at time of
             treatment

          -  No active CNS leukemia

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Bilirubin ≤ 1.5 mg/dL

          -  ALT and AST &lt; 2.5 times upper limit of normal

          -  Albumin ≥ 3 mg/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  LVEF ≥ 50%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 2 weeks after
             completion of study treatment

          -  No complicated medical or psychiatric problems that would preclude study compliance

          -  No concurrent serious uncontrolled infection or disseminated intravascular coagulation

          -  No myocardial infarction within the past 6 months

          -  No allergies to diphtheria toxin

          -  No requirement for oxygen

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other concurrent antineoplastic drugs

          -  No concurrent radiotherapy

          -  No concurrent corticosteroids as antiemetics

          -  No concurrent hematopoietic growth factors (e.g., epoetin alfa, interleukin-11,
             filgrastim [G-CSF], or sargramostim [GM-CSF])

          -  No concurrent intravenous immunoglobins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur E. Frankel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <results_first_submitted>November 21, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>blastic plasmacytoid dendritic cell neoplasm</keyword>
  <keyword>plasmacytoid dendritic cell leukemia</keyword>
  <keyword>CD123+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT00397579/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SL-401</title>
          <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
DT388IL3: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with BPDCN treated with SL-401.</population>
      <group_list>
        <group group_id="B1">
          <title>SL-401</title>
          <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
DT388IL3: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="40" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response</title>
        <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
Response to Treatment will be evaluated as follows:
Complete response (CR): patient has a normal whole blood count; platelets with absent blasts in peripheral blood or marrow; no evidence of nodal involvement or liver/spleen involvement; no skin lesion involvement.
Partial Response (PR); patient experiences a decrease of 50% or more in marrow blasts and skin lesions; and there is a decrease in the size of the nodes/liver/spleen.
Stable Disease (SD); failure to achieve at least PR, and there is no evidence of progression for 2 months.
Failure: death during treatment or disease progression characterized by an increase in the percentage bone marrow blast or an increase in skin or node/liver or spleen size.
Reported is the percentage of participants experiencing either CR, PR or SD.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SL-401</title>
            <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
DT388IL3: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response</title>
          <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
Response to Treatment will be evaluated as follows:
Complete response (CR): patient has a normal whole blood count; platelets with absent blasts in peripheral blood or marrow; no evidence of nodal involvement or liver/spleen involvement; no skin lesion involvement.
Partial Response (PR); patient experiences a decrease of 50% or more in marrow blasts and skin lesions; and there is a decrease in the size of the nodes/liver/spleen.
Stable Disease (SD); failure to achieve at least PR, and there is no evidence of progression for 2 months.
Failure: death during treatment or disease progression characterized by an increase in the percentage bone marrow blast or an increase in skin or node/liver or spleen size.
Reported is the percentage of participants experiencing either CR, PR or SD.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SL-401</title>
          <description>Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
DT388IL3: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Office</name_or_title>
      <organization>University of Texas Southwestern Medical Center at Dallas</organization>
      <phone>214-648-7097</phone>
      <email>studyfinder@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

